Royal Bank of Canada’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $8.28M | Buy |
295,000
+210,000
| +247% | +$5.59M | ﹤0.01% | 2050 |
|
|
2025
Q4 | $2.12M | Sell |
85,000
-57,900
| -41% | -$1.46M | ﹤0.01% | 3103 |
|
|
2025
Q3 | $3.64M | Buy |
+142,900
| New | +$3.53M | ﹤0.01% | 2907 |
|
|
2025
Q1 | – | Sell |
-210,900
| Closed | -$5.59M | – | 7142 |
|
|
2024
Q4 | $5.59M | Sell |
210,900
-573,100
| -73% | -$15.5M | ﹤0.01% | 2223 |
|
|
2024
Q3 | $22.7M | Buy |
784,000
+6,400
| +0.8% | +$187K | ﹤0.01% | 1269 |
|
|
2024
Q2 | $21.8M | Buy |
777,600
+395,200
| +103% | +$10.9M | 0.01% | 1204 |
|
|
2024
Q1 | $10.6M | Buy |
382,400
+282,900
| +284% | +$7.85M | ﹤0.01% | 1639 |
|
|
2023
Q4 | $2.87M | Buy |
99,500
+69,500
| +232% | +$2.1M | ﹤0.01% | 2739 |
|
|
2023
Q3 | $995K | Sell |
30,000
-45,400
| -60% | -$1.61M | ﹤0.01% | 3444 |
|
|
2023
Q2 | $2.77M | Buy |
75,400
+65,100
| +632% | +$2.53M | ﹤0.01% | 2578 |
|
|
2023
Q1 | $420K | Sell |
10,300
-159,800
| -94% | -$6.9M | ﹤0.01% | 4016 |
|
|
2022
Q4 | $8.72M | Sell |
170,100
-51,500
| -23% | -$2.47M | ﹤0.01% | 1721 |
|
|
2022
Q3 | $9.7M | Buy |
221,600
+51,500
| +30% | +$2.5M | ﹤0.01% | 1561 |
|
|
2022
Q2 | $8.92M | Hold |
170,100
| – | – | ﹤0.01% | 1648 |
|
|
2022
Q1 | $8.81M | Buy |
170,100
+134,200
| +374% | +$6.96M | ﹤0.01% | 1808 |
|
|
2021
Q4 | $2.12M | Sell |
35,900
-110,100
| -75% | -$5.46M | ﹤0.01% | 3107 |
|
|
2021
Q3 | $6.28M | Buy |
146,000
+110,100
| +307% | +$4.88M | ﹤0.01% | 2150 |
|
|
2021
Q2 | $1.41M | Sell |
35,900
-50,000
| -58% | -$1.94M | ﹤0.01% | 3365 |
|
|
2021
Q1 | $3.11M | Hold |
85,900
| – | – | ﹤0.01% | 2632 |
|
|
2020
Q4 | $3.16M | Buy |
+85,900
| New | +$3.15M | ﹤0.01% | 2532 |
|
|
2020
Q2 | – | Sell |
-727,260
| Closed | -$22.5M | – | 6836 |
|
|
2020
Q1 | $22.5M | Sell |
727,260
-107,508
| -13% | -$3.66M | 0.01% | 843 |
|
|
2019
Q4 | $31M | Hold |
834,768
| – | – | 0.01% | 876 |
|
|
2019
Q3 | $28.5M | Sell |
834,768
-789,446
| -49% | -$28.7M | 0.01% | 856 |
|
|
2019
Q2 | $66.8M | Buy |
1,624,214
+1,093,420
| +206% | +$43.4M | 0.03% | 477 |
|
|
2019
Q1 | $21.4M | Buy |
530,794
+522,678
| +6,440% | +$20.9M | 0.01% | 1021 |
|
|
2018
Q4 | $336K | Sell |
8,116
-202,684
| -96% | -$8.41M | ﹤0.01% | 4006 |
|
|
2018
Q3 | $8.81M | Sell |
210,800
-158,100
| -43% | -$6.09M | ﹤0.01% | 1689 |
|
|
2018
Q2 | $12.7M | Sell |
368,900
-21,080
| -5% | -$720K | 0.01% | 1366 |
|
|
2018
Q1 | $13.1M | Sell |
389,980
-5,902
| -1% | -$203K | 0.01% | 1358 |
|
|
2017
Q4 | $13.6M | Buy |
395,882
+195,833
| +98% | +$6.68M | 0.01% | 1397 |
|
|
2017
Q3 | $6.78M | Sell |
200,049
-45,533
| -19% | -$1.46M | ﹤0.01% | 1791 |
|
|
2017
Q2 | $7.83M | Buy |
245,582
+98,022
| +66% | +$3.09M | ﹤0.01% | 1665 |
|
|
2017
Q1 | $4.79M | Sell |
147,560
-1,816,569
| -92% | -$57.3M | ﹤0.01% | 1942 |
|
|
2016
Q4 | $60.5M | Buy |
1,964,129
+1,042,301
| +113% | +$31.8M | 0.03% | 446 |
|
|
2016
Q3 | $29.6M | Sell |
921,828
-301,023
| -25% | -$10.1M | 0.02% | 757 |
|
|
2016
Q2 | $40.9M | Buy |
1,222,851
+1,015,529
| +490% | +$32.4M | 0.02% | 552 |
|
|
2016
Q1 | $5.83M | Sell |
207,322
-677,195
| -77% | -$19.3M | ﹤0.01% | 1723 |
|
|
2015
Q4 | $27.1M | Buy |
884,517
+700,067
| +380% | +$22M | 0.02% | 760 |
|
|
2015
Q3 | $5.5M | Buy |
+184,450
| New | +$5.91M | ﹤0.01% | 1531 |
|
|
2015
Q2 | – | Sell |
-574,219
| Closed | -$19M | – | 6681 |
|
|
2015
Q1 | $19M | Buy |
+574,219
| New | +$18.3M | 0.01% | 852 |
|
|
2014
Q4 | – | Sell |
-462,495
| Closed | -$13M | – | 6264 |
|
|
2014
Q3 | $13M | Buy |
+462,495
| New | +$13M | 0.01% | 1060 |
|
|
2014
Q1 | – | Sell |
-316,200
| Closed | -$9.19M | – | 6082 |
|
|
2013
Q4 | $9.19M | Buy |
316,200
+118,364
| +60% | +$3.44M | 0.01% | 1247 |
|
|
2013
Q3 | $5.39M | Sell |
197,836
-3,041,528
| -94% | -$82.8M | ﹤0.01% | 1537 |
|
|
2013
Q2 | $86.1M | Buy |
+3,239,364
| New | +$89.5M | 0.07% | 193 |
|
Other funds holding PFE
VCM
VPM
Royal Bank of Canada's PFE Position: Q1 2026 in Review
Royal Bank of Canada reduced its Pfizer (PFE) stake by 4.8% in Q1 2026, selling an estimated $45.6M and leaving 34,155,840 shares worth $959M. The position accounts for 0.17% of the portfolio, ranked #114.
Royal Bank of Canada first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.63B in Q4 2021. 2,947 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Royal Bank of Canada held 34,155,840 shares of Pfizer worth $959M as of Q1 2026.
- Royal Bank of Canada sold 1,714,429 Pfizer shares in Q1 2026, an estimated $45.6M.
- Pfizer made up 0.17% of Royal Bank of Canada's portfolio in Q1 2026, its #114 holding.
- Royal Bank of Canada first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
- Royal Bank of Canada's Pfizer position peaked at $1.63B in Q4 2021.
- 2,947 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.